Nexgram Biomedic aims to grow into a Fully Integrated Global Pharmaceutical Company (Global FIPCO), equipped with an entire value chain ranging from development and manufacturing to commercialization via our own sales and marketing organization.
Nexgram Biomedic subsidiaries commenced research and development of new medical devices back in year 1993 as part of our search for the next-generation growth engine of Nexgram Group. The company’s hospital medical devices including face and body shield, surgical intubation and public protection devices, as well as disposable medical gloves and personal protection equipment are sold worldwide.
In Year 2017, Nexgram Group was ahead of time in the research of Muslim friendly halal human vaccine manufacturing business. The Group invested further in year 2019 on stem-cell facility master plan in Cyberjaya, Malaysia.
The exciting ascent of Nexgram Biomedic began with development of TracvirusTM in March 2020, the company’s first clinical and laboratory health record management platform for mass screening and monitoring purposes by corporate and authorities. The company became the first Malaysian company independently developed an investigational anti-fraud and anti-fake Electronic Certificate specifically for Covid-19 test and vaccination records verification.
In addition, the company also cooperates with industry experts in the research for the development of drugs and vaccine for Covid-19, as well as other molecular diagnostic treatments for cancer, and anti-aging formulas.
“We decode life for better life”Nexgram Biomedic Vision & Mission
“We connect health with happiness”